Vestal Point Capital, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001974915

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 69 positions · Total reported value $1.32B · Top-10 concentration 48.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 14 new · 20 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, Vestal Point Capital, LP disclosed 69 equity positions with a combined reported value of $1.32B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were INSM ($116.80M), JAZZ ($100.27M), CYTK ($79.20M). By sector, the heaviest allocations are Health Care 70.6%, Industrials 1.8%. Versus the prior quarter, allocation shifted toward Other (+5.8pp), Industrials (+1.8pp) and away from Health Care (-7.6pp).

Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 52% of names.

The largest new positions opened in Q3 2024 were AGIO ($33.77M), BMRN ($28.12M), AVDL ($26.23M).

Of the 19 positions fully exited versus the prior quarter, the largest were GMED ($61.64M), ONC ($49.93M), EXAS ($39.08M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • AGIO AGIOS PHARMACEUTICALS INC · $33.77M
  • BMRN BIOMARIN PHARMACEUTICAL INC · $28.12M
  • AVDL AVADEL PHARMACEUTICALS · $26.23M
  • BHVN BIOHAVEN LTD · $24.98M
  • EW EDWARDS LIFESCIENCES CORP · $18.15M
  • GILD GILEAD SCIENCES INC · $16.77M
  • A AGILENT TECHNOLOGIES INC · $14.85M
  • GSK GSK PLC · $12.26M

Fully Exited (vs previous quarter)

  • GMED GLOBUS MED INC · prev qtr: $61.64M · history
  • ONC BEONE MEDICINES LTD · prev qtr: $49.93M
  • EXAS EXACT SCIENCES CORP COM · prev qtr: $39.08M
  • AXSM AXSOME THERAPEUTICS INC. · prev qtr: $24.15M
  • ALXO ALX ONCOLOGY HLDGS INC · prev qtr: $21.71M
  • PRAX PRAXIS PRECISION MEDICINES I · prev qtr: $18.20M
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $12.85M
  • IMNM IMMUNOME INC · prev qtr: $12.10M

Insider Transactions (Form 4)

Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-127682 (status: Approved), registered 2023-04-14
  • Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: vestalpoint.com

Portfolio Structure

  • 63 positions · $3.87B reported value (Q3 2026)
  • Top 10 holdings = 67.3% of reported value
  • Largest position: ABVX (ABIVAX SA) at 10.1%
  • Average position size: $61.44M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 70.6%
Other 27.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.60M $116.80M 8.86%
8.86%
Add
2 900.00K $100.27M 7.60%
7.60%
Reduce
3 1.50M $79.20M 6.01%
6.01%
Reduce
4 1.55M $63.92M 4.85%
4.85%
Add
5 675.00K $56.37M 4.28%
4.28%
Hold
6 1.15M $50.47M 3.83%
3.83%
Add
7 4.00M $46.32M 3.51%
3.51%
Add
8 4.00M $44.04M 3.34%
3.34%
Add
9 3.75M $42.79M 3.25%
3.25%
Add
10 750.00K $41.66M 3.16%
3.16%
Reduce
11 250.00K $37.33M 2.83%
2.83%
Reduce
12 720.00K $36.35M 2.76%
2.76%
Reduce
13 2.50M $34.83M 2.64%
2.64%
Add
14 8.09M $34.30M 2.60%
2.60%
Add
15 760.00K $33.77M 2.56%
2.56%
New
16 825.00K $32.48M 2.46%
2.46%
Add
17 400.00K $28.12M 2.13%
2.13%
New
18 2.00M $26.23M 1.99%
1.99%
New
19 500.00K $24.98M 1.90%
1.90%
New
20 4.75M $23.42M 1.78%
1.78%
Hold
21 485.00K $22.03M 1.67%
1.67%
Reduce
22 5.03M $21.87M 1.66%
1.66%
Add
23 2.80M $19.52M 1.48%
1.48%
Add
24 275.00K $18.15M 1.38%
1.38%
New
25 200.00K $16.77M 1.27%
1.27%
New
26 1.50M $15.00M 1.14%
1.14%
Reduce
27 100.00K $14.85M 1.13%
1.13%
New
28 250.00K $12.94M 0.98%
0.98%
Reduce
29 300.00K $12.26M 0.93%
0.93%
New
30 425.00K $10.82M 0.82%
0.82%
New
31 395.00K $10.82M 0.82%
0.82%
Reduce
32 205.00K $10.48M 0.79%
0.79%
New
33 1.02M $10.47M 0.79%
0.79%
Reduce
34 1.15M $9.73M 0.74%
0.74%
Reduce
35 425.00K $9.55M 0.72%
0.72%
Reduce
36 150.00K $8.64M 0.66%
0.66%
New
37 125.00K $8.63M 0.66%
0.66%
New
38 136.50K $8.02M 0.61%
0.61%
New
39 615.00K $7.72M 0.58%
0.58%
Add
40 850.00K $7.68M 0.58%
0.58%
Add
41 230.00K $7.56M 0.57%
0.57%
New
42 650.00K $7.44M 0.56%
0.56%
Add
43 30.00K $7.23M 0.55%
0.55%
New
44 30.00K $6.37M 0.48%
0.48%
New
45 125.00K $6.09M 0.46%
0.46%
New
46 1.69M $5.90M 0.45%
0.45%
Reduce
47 180.00K $5.18M 0.39%
0.39%
Hold
48 400.00K $5.08M 0.39%
0.39%
New
49 930.00K $4.93M 0.37%
0.37%
Add
50 1.05M $4.77M 0.36%
0.36%
New

FAQ

What did Vestal Point Capital, LP buy in 2024-Q3?

In its 2024-Q3 13F filing, Vestal Point Capital, LP reported 69 equity positions worth $1.32B in aggregate; its largest disclosed positions were INSM ($116.80M), JAZZ ($100.27M), CYTK ($79.20M).

How large is Vestal Point Capital, LP's portfolio?

Vestal Point Capital, LP reported $1.32B of long equity holdings across 69 positions as of 2024-Q3. Top-10 holdings account for 48.7% of reported value.

What is Vestal Point Capital, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/vestal-point-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →